Publications by authors named "Neill Giese"

Claim this Profile
T
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Julia Hoellenriegel, Sarah A Meadows, Mariela Sivina, William G Wierda, Hagop Kantarjian, Neill Giese

Blood· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
Brian J Lannutti, Sarah A Meadows, Sarah E M Herman, Adam Kashishian, Bart Steiner, Neill A Giese

Blood· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti, Giulia Perrone, Naoya Miura, Neill A Giese

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Sarah E M Herman, Amber L Gordon, Amy J Wagner, Nyla A Heerema, Weiqiang Zhao, Neill A Giese

Blood· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Jennifer L Rocnik, Rachel Okabe, Jin-Chen Yu, Benjamin H Lee, Neill Giese

Blood· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
Hanna S Radomska, Daniela S Bassères, Rui Zheng, Pu Zhang, Tajhal Dayaram, Neill A Giese

J Exp Med· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Ian J Griswold, Lei J Shen, Paul La Rosée, Shadmehr Demehri, Michael C Heinrich, Neill Giese

Blood· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
Jennifer J Clark, Jan Cools, David P Curley, Jin-Chen Yu, Nathalie A Lokker, Neill A Giese

Blood· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.
Julie A Heath, Mukund M Mehrotra, Shannon Chi, Jin-Chen Yu, Athiwat Hutchaleelaha, Neill A Giese

Bioorg Med Chem Lett· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDGF C is a selective alpha platelet-derived growth factor receptor agonist that is highly expressed in platelet alpha granules and vascular smooth muscle.
Li Fang, Yibing Yan, Laszlo G Komuves, Shirlee Yonkovich, Carol M Sullivan, Neill A Giese

Arterioscler Thromb Vasc Biol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Kenji Matsuno, Junko Ushiki, Takashi Seishi, Michio Ichimura, Neill A Giese

J Med Chem· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. Part 4: structure-activity relationships for substituents on the quinazoline moiety of 4-[4-(N-substituted(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Kenji Matsuno, Takashi Seishi, Takao Nakajima, Michio Ichimura, Neill A Giese

Bioorg Med Chem Lett· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.
Koichi Kozaki, Wolfgang E Kaminski, Jingjing Tang, Stan Hollenbach, Per Lindahl, Neill A Giese

Am J Pathol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective inhibitors of PDGF receptor phosphorylation. 2. Synthesis, structure activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.
Kenji Matsuno, Takao Nakajima, Michio Ichimura, Neill A Giese, Jin-Chen Yu

J Med Chem· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Anjali Pandey, Deborah L Volkots, Joseph M Seroogy, Jack W Rose, Jin-Chen Yu, Neill A Giese

J Med Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.
Kenji Matsuno, Michio Ichimura, Takao Nakajima, Keiko Tahara, Shigeki Fujiwara, Neill A Giese

J Med Chem· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Nathalie A Lokker, Carol M Sullivan, Stanley J Hollenbach, Mark A Israel, Neill A Giese

Cancer Res· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
Louise M Kelly, Jin-Chen Yu, Christina L Boulton, Mutiah Apatira, Jason Li, Neill A Giese

Cancer Cell· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis